1 Compliance vs. the Law Department: How to Work Together Michael Dusseau Senior Director, Compliance North America Schering-Plough David Ralston, Esq.

Slides:



Advertisements
Similar presentations
4.02 Compliance Training Brian A. Dahl Senior Counsel Takeda Pharmaceuticals North America, Inc. November 14, 2003.
Advertisements

Pharmaceutical Congress Spring 2003 Preconference Symposia Compliance 101 for Pharmaceutical Manufacturers Michael P. Swiatocha June 8, 2003.
Integrating Ethics Into Your Compliance Program John A. Gallagher, Ph.D Center for Ethics in Health Care Atlanta, GA.
Presented By: Tracy Johnson, Central CAPT
© 2013 Cengage Learning. All Rights Reserved. 1 Part Four: Implementing Business Ethics in a Global Economy Chapter 8: Developing an Effective Ethics Program.
CORPORATE COMPLIANCE OVERVIEW David Meisels OSB Corporate Counsel Roundtable April 26, 2012.
Supplier Ethics: Program Checklist
Corporate Ethics Compliance *
Health Sciences.  Principles  Code of Conduct for right and wrong  Values  Core of all health care decisions.
How the Balance Scorecard Approach Compares to Policy Governance ® IPGA 2007 Annual Conference Alexandria, VA June 23, 2007 Presented by: David Mustine.
Internal Auditing and Outsourcing
Corporate Social Responsibility- do we need a Statutory Instrument? Presented to the Zambia Alternative Mining Indaba conference- July 17, 2013 Sombo Chunda,
Component 2: The Culture of Health Care Unit 3: Health Care Settings— The Places Where Care Is Delivered Lecture 3 This material was developed by Oregon.
Developing an Effective Ethics Program.  The responsibility of the corporation as a moral agent  The need for organizational ethics programs  An effective.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
CORPORATE COMPLIANCE Tim Timmons Vice President Compliance and Regulatory Services Health Future, LLC.
Stakeholders and Ethics Organizational Stakeholders Stakeholders: people who have an interest, claim, or stake in an organization  Inside stakeholders.
Institutional Research Compliance Juliann Tenney, JD Research Compliance and Privacy Officer Director, Institutional Research Compliance Program.
Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.
Chapter 1 Introduction Managers and Managing.
Presentation to Senior Management MiFID for Senior Managers Introduction These slides introduce the big changes for senior management from MiFID.
Developing an Effective Ethics Program
Managing the Privacy Function at a Large Company Kimberly S. Gray, Esq., CIPP Chief Privacy Officer Highmark Inc.
Establishing A Compliance Program: It Makes Sense
SCHERING-PLOUGH INTERNATIONAL Building an International Compliance Program An Operational Approach Dalton Smart CPA, MBA Schering-Plough International.
Basic Concepts in Management. Manager Someone who coordinates and oversee the work of other people so that organizational goal can be achieved.
Corporate Responsibility and Compliance A Resource for Health Care Boards of Directors By Debbie Troklus, CHC and Michael C. Hemsley, Esq.
2005 Continuity Planning where the rubber meets the road.
Annual seminar in Berlin – 27 th May Should EU corporate governance measures take into account the size of listed companies ? How ? Should a.
Conducting Compliance Assessments and Building Internal Controls In Pharmaceutical R&D Third Annual Medical Research Summit – Session 2.01 Michael Swiatocha.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Pre-Conference III: Auditing, Monitoring and Effective Internal Investigations Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
GDS_ _v1 1 Building an Ethics & Compliance Program Presented by  Steve Vincze TAP Ethics & Compliance Officer Presented by  Steve Vincze TAP Ethics.
Roadmap For An Effective Compliance And Ethics Program The Top Ten Things the Board Must Know [Name of Presenter] [Title] [Date]
DIRECT WORKS FORUM 10 June 2008 Andy Ballard. COMMON LAW MANSLAUGHTER Effectively – Death by gross negligence Test – (a) was a (common law) duty of care.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
Strategic Approaches to Improving Ethical Behavior
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
Setting the Scene: The Role of Ethics and Compliance in the Biopharmaceutical Market.
Influencing the ethical context of your organisation Speaker: June Smith, Partner Company: The Argyle Partnership Lawyers Date: 22 November 2006.
Implementing an Effective Global Anti-Bribery Program Implementing an Effective Global Anti-Bribery Program Elaine Murphy, MBA Director Health Care Compliance.
How to Operationalize the Guidance In A Pharmaceutical Company OIG Guidance Pharma Audioconference Doug Lankler May 21, 2003.
An Overview: The Role of the Audit Committee in Monitoring, Oversight, and Compliance Derry Harper, Inspector General and Director of Compliance.
Agenda for Session Compliance in Clinical Research
Session 1.01 US Healthcare Professionals Abroad – Issues and Practical Solutions Caroline West – Senior VP, Chief Compliance and Risk Officer Shire Pharmaceuticals.
Patrick Sulzberger, CPA, CHC Compliance & The Board A Guide to Excellence.
RECOMMENDATIONS OF THE GOVERNOR ’ S TASK FORCE ON CONTRACTING AND PROCUREMENT REVIEW Report Overview PD Customer Forum September 2002.
The Second Annual Medical Device Regulatory, Reimbursement and Compliance Congress Presented by J. Glenn George Thursday, March 29, 2007 Day II – Track.
Building A Pharmaceutical Compliance Program Presentation to the Sixth Annual Congress on Health Care Compliance February 7, 2003 Janice Toran Fujisawa.
Legal Jeopardy: Whose Risk Is It?. SPEAKERS Jason Straight Chief Privacy Officer and Senior Vice President Cyber Risk Solutions at UnitedLex Patrick Manzo.
The Use of Actuaries as Part of a Supervisory Model Michael Hafeman – Consultant World Bank May 2004.
0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
Copyright © 2015 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
Governance, Risk and Ethics. 2 Section A: Governance and responsibility Section B: Internal control and review Section C: Identifying and assessing risk.
Copyright © Houghton Mifflin Company. All rights reserved.8-1 Chapter 8 Developing an Effective Ethics Program.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Introduction 2. Pharmaceutical care is a professional patient care practice, which, when provided as an organized service, is experienced, documented,
Introduction to Enterprise Risk Management (“ERM”)
Roadmap For An Effective Compliance And Ethics Program
MGMT 452 Corporate Social Responsibility
Developing an Effective Ethics Program
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
Chapter 8 Developing an Effective Ethics Program
Risk Management: why and how to protect your health center
Kenya Mann Faulkner Chief Ethics & Compliance Officer April 2019
Internal Audit’s Role in Preventing Fraud and Corruption
Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual.
PRESENTATION TO PORTFOLIO COMMITTEE ON DMR 2010/ 11 ANNUAL REPORT
Presentation transcript:

1 Compliance vs. the Law Department: How to Work Together Michael Dusseau Senior Director, Compliance North America Schering-Plough David Ralston, Esq. Senior Legal Director Schering-Plough November 9, 2006 Compliance vs. the Law Department: How to Work Together Michael Dusseau Senior Director, Compliance North America Schering-Plough David Ralston, Esq. Senior Legal Director Schering-Plough November 9, 2006

2 Working Towards What? Embedding compliance into Company DNA Helping employees to base decisions on internal values, not external rules Transforming Company culture, not just creating new policies and procedures Taking these broad principles and applying them to the work of two specific departments -- Compliance and Law

3 Compliance vs. Law Department If the two departments are not working together, what result? –Business often plays one off the other in order to divide and conquer –Lawyers become policemen without training or expertise in compliance functions –Business doesn’t take ownership of their own issues, resulting in a rules-based versus a values-based organization

4 Compliance vs. Law? Working together, what result? –Law function supports compliance efforts –Law interpretations develop into compliance implementation –Compliance interfaces with business operations in ways that not only implement legal guidance, but also in ways that ultimately improve business processes –Values-based versus rules-based organization can evolve

5 Organizational Structure How Compliance fits within organizational structure often drives ultimate ability to effectively collaborate with Law –Compliance Organization within Law Department –Compliance Organization within Finance Department –Compliance Organization Reports Directly to CEO or Board of Directors

6 Compliance Program Guidance for Pharmaceutical Manufacturers The OIG believes it is generally not advisable for the compliance function to be subordinate to the pharmaceutical manufacturer’s general counsel, or comptroller or similar financial officer. Separating the compliance function from the key management positions of general counsel or chief financial officer, establishes a system of checks and balances that more effectively achieve the goals of the compliance program. See Office of Inspector General April 2003

7 Report Directly to CEO Presentation assumes Compliance Organization reports directly to CEO or Board of Directors Alternative Considerations: –Does structure subsume compliance function to other priorities within the Company? –Does tension exist between business goals and compliance goals? –Does structure end up promoting rules-based culture rather than values-based culture?

8 Compliance Program Development Does the Law Department have any role in developing a Compliance Program? Compliance Department drives process, but both bring needed expertise to the table –Compliance guides and advises business operations to develop policies and procedures specific to business operations –Law reviews documents based on core legal principles –Balanced approach between hyper-vigilant legal analysis versus ability to stay competitive within the marketplace Law and Compliance work together as agents for change within organization

9 Process Improvement Building compliance into a Company’s DNA means building compliance upstream in all Company processes Involving business in improving Company processes allows Compliance and Law to become trusted business partners, not just enforcement officers

10 Process Improvement Example Law and Compliance partner to improve Grant and Charitable Contributions process –PhRMA Code recommends removal of grants from sales and marketing –Law department evaluated current processes and recommended change –Compliance implemented process change to remove sales force from equation –Process improved by requiring qualified medical and scientific review of grants –Charitable contribution process centralized to create holistic approach to company giving

11 Process Improvement Result Sales reps able to concentrate on product education and promotion, not administrative details of grants and charitable contributions Allows physician interaction for specialty products like oncology to be spent on issues of ultimate value to patient health Prevents inappropriate linking of clinical decisions to financial decisions

12 Guidance and Advice Partner with business by early involvement of Compliance and Law in analysis of upcoming events and programs Provide parameters and underlying principles business can use to ultimately make business decision regarding events and programs Early involvement may also stop fatally flawed concepts from ever getting off the ground Cross-functional collaboration with business, Law and Compliance is more likely to result in initiatives that are both competitive within the marketplace and consistent with compliance objectives

13 Investigations Privilege Investigations –Different process altogether, not addressed here Non-privilege Investigations –Compliance receives information from hot-line, monitoring activity or from another investigation –Compliance seeks Law involvement to determine whether violation involves legal issues and/or policy and procedure issues –Law seeks Compliance involvement to resolve issues discovered through interaction with business

14 Investigation Completion Completion of investigation may result in corrective action –May involve Law department process improvement (changes to contract templates) labor law issues regarding employee disciplinary actions Before deciding on corrective action, always ask: did the individual break the policy, or was policy broken to begin with? Learning from investigations is an example of continuous improvement

15 Risk Assessment Law assesses legal risk –Advises business and Compliance Compliance assesses CIA, public relations and regulatory risk perceptions –Even if not a violation of law, what is possible perception created by this activity? Issues are rarely black and white; require team approach to risk assessment Compliance becomes a part of company DNA

16 Conclusion